Yu, Qiang

A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome

Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell

Genomics and Chromatin DynamicsCancer-related Molecular Pathways

Cited by 1,141

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development

Epigenetics and DNA MethylationChromatin Remodeling and Cancer

Cited by 895

Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis

Zhang, W. C., Shyh-Chang, N., Yang, H., Rai, A., Umashankar, S., Ma, S., Soh, B. S., Sun, L. L., Tai, B. C., Nga, M. E., et al. (2012) · Cell

Cancer, Hypoxia, and MetabolismCancer Cells and Metastasis

Cited by 660

Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer

Tang, Y.-A., Chen, Y.-F., Bao, Y., Mahara, S., Yatim, S. M. J. M., Oguz, G., Lee, P. L., Feng, M., Cai, Y., Tan, E. Y., et al. (2018) · Proceedings of the National Academy of Sciences

Cancer Cells and MetastasisCancer, Hypoxia, and Metabolism

Cited by 277

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., et al. (2022) · Nature Communications

Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and Metabolism

Cited by 200

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer

Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences

Epigenetics and DNA MethylationCancer, Hypoxia, and Metabolism

Cited by 87

Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer

Pek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 86